MedTrace Logo

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

NCT00373113 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 482

Last updated 2012-06-25

Study results available
· View outcomes & findings →

Summary

To compare efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast cancer who failed both a taxane and an anthracycline chemotherapy regimen or failed with a taxane and for whom further anthracycline therapy is not indicated

Conditions

  • Breast Neoplasms

Interventions

DRUG

Capecitabine

1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles

DRUG

Sunitinib malate

37.5 mg daily, continuous dosing

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-10-31
Completion
2011-06-30

Countries

  • Argentina
  • Australia
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • Colombia
  • France
  • Germany
  • Hong Kong
  • India
  • Italy
  • Japan
  • Mexico
  • Peru
  • Philippines
  • Singapore
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00373113 on ClinicalTrials.gov